Association between serum total cholesterol level and renal outcome in systemic lupus erythematosus.

OBJECTIVE To determine whether an elevated serum total cholesterol level in a first-available sample obtained at a systemic lupus erythematosus (SLE) clinic is associated with worse renal outcome in patients with SLE. METHODS Survival analysis methods were used on prospectively gathered data on 1,060 patients with SLE who were registered in the University of Toronto Lupus Databank. The effect of total cholesterol and 15 additional variables on the outcomes of renal deterioration, end-stage renal disease (ESRD), and death was assessed using Cox proportional hazards methods. RESULTS In 474 (45%) of the 1,060 patients, the total cholesterol level exceeded 5.2 mmoles/liter. In the entire study group, the median total cholesterol level was 5.1 mmoles/liter (range 1.6-17.1). During a mean followup period of 8.8 years, 93 patients (9%) experienced renal deterioration, 42 patients (4%) had ESRD, and 161 deaths occurred, 48 (30%) of which were associated with renal dysfunction (renal death), and 113 (70%) of which were not associated with renal dysfunction (nonrenal death). Kaplan-Meier survival estimates for each outcome were statistically significantly different between patients with normal versus those with elevated total cholesterol levels (cutoff 5.2 mmoles/ liter), with a worse outcome observed among those with an elevated total cholesterol concentration. In multivariate analyses, total cholesterol level (hazard ratio [HR] 1.17, 95 confidence interval [95% CI] 1.01-1.36), serum creatinine level (HR 1.06, 95% CI 1.04-1.07), proteinuria (HR 2.44, 95% CI 1.25-4.76), the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (HR 1.44, 95% CI 1.16-1.80), and corticosteroid dose (HR 1.01, 95% CI 1.00-1.02) were associated with renal deterioration. Significant predictors of ESRD were baseline proteinuria (HR 6.24, 95% CI 1.96-19.88) and serum creatinine level (HR 1.15, 95% CI 1.08-1.22). The total cholesterol level was correlated with death (HR 1.20, 95% CI 1.11-1.29), retaining statistical significance for renal death (HR 1.33, 95% CI 1.20-1.47) but not for nonrenal death (HR 1.12, 95% CI 0.99-1.25). CONCLUSION Those results indicate that an elevated serum total cholesterol level in a first-available sample obtained at an SLE clinic is associated with adverse renal outcomes and mortality.

[1]  D. Symmons,et al.  The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. , 1996, Arthritis and rheumatism.

[2]  J. Buring,et al.  Cholesterol and the risk of renal dysfunction in apparently healthy men. , 2003, Journal of the American Society of Nephrology : JASN.

[3]  B. Brenner,et al.  Analysis of metabolic parameters as predictors of risk in the RENAAL study. , 2003, Diabetes care.

[4]  L. Ruilope,et al.  Atorvastatin prevents glomerulosclerosis and renal endothelial dysfunction in hypercholesterolaemic rabbits. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[5]  R. Riggio,et al.  Systemic lupus erythematosus in patients with end-stage renal disease: long-term follow-up on the prognosis of patients and the evolution of lupus activity. , 1990, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[6]  V. Manninen,et al.  Effects of hypertension and dyslipidemia on the decline in renal function. , 1995, Hypertension.

[7]  M. Fujishima,et al.  Effects of anti-hyperlipidaemic agent or dietary protein restriction on progressive renal deterioration in adriamycin-induced nephropathy in rats. , 1993, International urology and nephrology.

[8]  R. Falk,et al.  Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network. , 1997, Kidney international.

[9]  D. Gladman,et al.  The effect of pregnancy on lupus nephritis. , 2004, Arthritis and rheumatism.

[10]  J. Kelsey,et al.  Estimates of the prevalence of selected arthritic and musculoskeletal diseases in the United States. , 1989, The Journal of rheumatology.

[11]  D. Wallace,et al.  Lupus nephritis: Experience with 230 patients in a private practice from 1950 to 1980 , 1982 .

[12]  Steĭnberg Ad.  The treatment of lupus nephritis. , 1986, Kidney international.

[13]  L. Moist,et al.  Management of chronic renal insufficiency in lupus nephritis: Role of proteinuria, hypertension and dyslipidemia in the progression of renal disease , 1998, Lupus.

[14]  B. Kasiske,et al.  Pharmacologic Treatment of Hyperlipidemia Reduces Glomerular Injury in Rat 5/6 Nephrectomy Model of Chronic Renal Failure , 1988, Circulation research.

[15]  K. Iseki,et al.  Triglyceride, but not total cholesterol or low-density lipoprotein cholesterol levels, predict development of proteinuria. , 2002, Kidney international.

[16]  H. Gröne,et al.  The role of lipids in nephrosclerosis and glomerulosclerosis. , 1994, Atherosclerosis.

[17]  N. Taub,et al.  Environmental factors predicting nephritis in systemic lupus erythematosus. , 1993, Annals of the rheumatic diseases.

[18]  J. Klippel,et al.  End-stage renal disease and systemic lupus erythematosus. , 1996, The American journal of medicine.

[19]  M. Reichlin,et al.  Autoantibodies to lipoprotein lipase and dyslipidemia in systemic lupus erythematosus. , 2002, Arthritis and rheumatism.

[20]  M. Ravid,et al.  Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. , 1998, Archives of internal medicine.

[21]  J. Coresh,et al.  Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. , 2000, Kidney international.

[22]  D. Gladman,et al.  Mortality studies in systemic lupus erythematosus. Results from a single center. II. Predictor variables for mortality. , 1995, The Journal of rheumatology.

[23]  J F Fries,et al.  The 1982 revised criteria for the classification of systemic lupus erythematosus. , 1982, Arthritis and rheumatism.

[24]  T. Chan,et al.  Efficacy of Mycophenolate Mofetil in Patients with Diffuse Proliferative Lupus Nephritis , 2000 .

[25]  B. Kasiske,et al.  Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. , 1988, Kidney international.

[26]  D. Gladman,et al.  Accelerated atheroma in lupus—background , 2000, Lupus.

[27]  H. Taylor,et al.  Traditional and nontraditional risk factors for cardiovascular and renal disease in African Americans (Part 2): a project of the Jackson Heart Study investigators. , 2002, The American journal of the medical sciences.

[28]  A. Eddy,et al.  Interstitial fibrosis in hypercholesterolemic rats: role of oxidation, matrix synthesis, and proteolytic cascades. , 1998, Kidney international.

[29]  J. Piette,et al.  Renal involvement in systemic lupus erythematosus. A study of 180 patients from a single center. , 1999, Medicine.

[30]  E. Bonfá,et al.  Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies , 1997, Lupus.

[31]  I. Bruce,et al.  Natural history of hypercholesterolemia in systemic lupus erythematosus. , 1999, The Journal of rheumatology.

[32]  B. Kasiske,et al.  Effect of lipid reduction on the progression of renal disease: a meta-analysis. , 2001, Kidney international.

[33]  K. Leong,et al.  Lipid profiles in patients with systemic lupus erythematosus. , 1994, The Journal of rheumatology.

[34]  T. Harrer,et al.  Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus , 2002, Annals of the rheumatic diseases.

[35]  M. Vilardell‐Tarrés,et al.  Predictors of poor renal outcome in patients with lupus nephritis treated with combined pulses of cyclophosphamide and methylprednisolone , 2003, Lupus.

[36]  J. Berden,et al.  Systemic lupus erythematosus: analysis of disease activity in 55 patients with end-stage renal failure treated with hemodialysis or continuous ambulatory peritoneal dialysis , 1990 .

[37]  E. Munthe.  Long-Term Studies , 1978 .

[38]  M. Jacobson,et al.  Dyslipoproteinemia in pediatric systemic lupus erythematosus. , 1988 .

[39]  T. Einarson,et al.  HOPE Study Impact on ACE Inhibitors Use , 2003, The Annals of pharmacotherapy.

[40]  H. Wedel,et al.  Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[41]  D. Sackett,et al.  Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. , 1992, Arthritis and rheumatism.

[42]  M. Karnovsky,et al.  Exacerbation of chronic aminonucleoside nephrosis by dietary cholesterol supplementation. , 1987, Kidney international.

[43]  Wellmann Kf,et al.  Renal changes in experimental hypercholesterolemia in normal and in subdiabetic rabbits. II. Long term studies. , 1971 .

[44]  A. Hamsten,et al.  TNF-α: a link between hypertriglyceridaemia and inflammation in SLE patients with cardiovascular disease , 2003 .

[45]  W. Mccune,et al.  Lupus nephritis. Classification, prognosis, immunopathogenesis, and treatment. , 1994, Rheumatic diseases clinics of North America.

[46]  L. Peric-Golia,et al.  Aortic and renal lesions in hypercholesterolemic adult, male, virgin sprague-dawley rats. , 1983, Atherosclerosis.

[47]  K. Stenzel,et al.  End-stage renal disease in systemic lupus erythematosus. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[48]  H. van Goor,et al.  Ovariectomy decreases plasma triglyceride levels and both prevents and alleviates glomerular disease in uninephrectomized female analbuminemic rats. , 1996, Journal of the American Society of Nephrology : JASN.

[49]  H. Taylor,et al.  Lipid Abnormalities and Renal Disease: Is Dyslipidemia a Predictor of Progression of Renal Disease? , 2003, The American journal of the medical sciences.

[50]  M. García-Carrasco,et al.  Cardiovascular risk factors and the long-term outcome of lupus nephritis. , 2001, QJM : monthly journal of the Association of Physicians.

[51]  A. Ciampi,et al.  The longterm prognosis of lupus nephritis: the impact of disease activity. , 1993, Journal of Rheumatology.